Optimal Dose-Setting Study of Curcumin for Improvement of Left Ventricular Systolic Function After Myocardial Infarction in Rats

Abstract.: A natural p300-specific histone acetyltransferase inhibitor, curcumin, may have a therapeutic potential for heart failure. However, a study of curcumin to identify an appropriate dose for heart failure has yet to be performed. Rats were subjected to a left coronary artery ligation. One we...

Full description

Bibliographic Details
Main Authors: Yoichi Sunagawa, Shogo Sono, Yasufumi Katanasaka, Masafumi Funamoto, Sae Hirano, Yusuke Miyazaki, Yuya Hojo, Hidetoshi Suzuki, Eriko Morimoto, Akira Marui, Ryuzo Sakata, Morio Ueno, Hideaki Kakeya, Hiromichi Wada, Koji Hasegawa, Tatsuya Morimoto
Format: Article
Language:English
Published: Elsevier 2014-04-01
Series:Journal of Pharmacological Sciences
Online Access:http://www.sciencedirect.com/science/article/pii/S134786131930091X
id doaj-2559959b473d4538b6b2e6c4143a1dc9
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Yoichi Sunagawa
Shogo Sono
Yasufumi Katanasaka
Masafumi Funamoto
Sae Hirano
Yusuke Miyazaki
Yuya Hojo
Hidetoshi Suzuki
Eriko Morimoto
Akira Marui
Ryuzo Sakata
Morio Ueno
Hideaki Kakeya
Hiromichi Wada
Koji Hasegawa
Tatsuya Morimoto
spellingShingle Yoichi Sunagawa
Shogo Sono
Yasufumi Katanasaka
Masafumi Funamoto
Sae Hirano
Yusuke Miyazaki
Yuya Hojo
Hidetoshi Suzuki
Eriko Morimoto
Akira Marui
Ryuzo Sakata
Morio Ueno
Hideaki Kakeya
Hiromichi Wada
Koji Hasegawa
Tatsuya Morimoto
Optimal Dose-Setting Study of Curcumin for Improvement of Left Ventricular Systolic Function After Myocardial Infarction in Rats
Journal of Pharmacological Sciences
author_facet Yoichi Sunagawa
Shogo Sono
Yasufumi Katanasaka
Masafumi Funamoto
Sae Hirano
Yusuke Miyazaki
Yuya Hojo
Hidetoshi Suzuki
Eriko Morimoto
Akira Marui
Ryuzo Sakata
Morio Ueno
Hideaki Kakeya
Hiromichi Wada
Koji Hasegawa
Tatsuya Morimoto
author_sort Yoichi Sunagawa
title Optimal Dose-Setting Study of Curcumin for Improvement of Left Ventricular Systolic Function After Myocardial Infarction in Rats
title_short Optimal Dose-Setting Study of Curcumin for Improvement of Left Ventricular Systolic Function After Myocardial Infarction in Rats
title_full Optimal Dose-Setting Study of Curcumin for Improvement of Left Ventricular Systolic Function After Myocardial Infarction in Rats
title_fullStr Optimal Dose-Setting Study of Curcumin for Improvement of Left Ventricular Systolic Function After Myocardial Infarction in Rats
title_full_unstemmed Optimal Dose-Setting Study of Curcumin for Improvement of Left Ventricular Systolic Function After Myocardial Infarction in Rats
title_sort optimal dose-setting study of curcumin for improvement of left ventricular systolic function after myocardial infarction in rats
publisher Elsevier
series Journal of Pharmacological Sciences
issn 1347-8613
publishDate 2014-04-01
description Abstract.: A natural p300-specific histone acetyltransferase inhibitor, curcumin, may have a therapeutic potential for heart failure. However, a study of curcumin to identify an appropriate dose for heart failure has yet to be performed. Rats were subjected to a left coronary artery ligation. One week later, rats with a moderate severity of myocardial infarction (MI) were randomly assigned to 4 groups receiving the following: a solvent as a control, a low dose of curcumin (0.5 mg∙kg−1∙day−1), a medium dose of curcumin (5 mg∙kg−1∙day−1), or a high dose of curcumin (50 mg∙kg−1∙day−1). Daily oral treatment was continued for 6 weeks. After treatment, left ventricular (LV) fractional shortening was dose-dependently improved in the high-dose (25.2% ± 1.6%, P < 0.001 vs. vehicle) and medium-dose (19.6% ± 2.4%) groups, but not in the low-dose group (15.5% ± 1.4%) compared with the vehicle group (15.1% ± 0.8%). The histological cardiomyocyte diameter and perivascular fibrosis as well as echocardiographic LV posterior wall thickness dose-dependently decreased in the groups receiving high and medium doses. The beneficial effects of oral curcumin on the post-MI LV systolic function are lower at 5 compared to 50 mg∙kg−1∙day−1 and disappear at 0.5 mg∙kg−1∙day−1. To clinically apply curcumin therapy for heart failure patients, a precise, optimal dose-setting study is required. Keywords:: curcumin, heart failure, hypertrophy, dose-dependency, p300
url http://www.sciencedirect.com/science/article/pii/S134786131930091X
work_keys_str_mv AT yoichisunagawa optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats
AT shogosono optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats
AT yasufumikatanasaka optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats
AT masafumifunamoto optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats
AT saehirano optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats
AT yusukemiyazaki optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats
AT yuyahojo optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats
AT hidetoshisuzuki optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats
AT erikomorimoto optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats
AT akiramarui optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats
AT ryuzosakata optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats
AT morioueno optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats
AT hideakikakeya optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats
AT hiromichiwada optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats
AT kojihasegawa optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats
AT tatsuyamorimoto optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats
_version_ 1724957645524172800
spelling doaj-2559959b473d4538b6b2e6c4143a1dc92020-11-25T02:01:17ZengElsevierJournal of Pharmacological Sciences1347-86132014-04-011264329336Optimal Dose-Setting Study of Curcumin for Improvement of Left Ventricular Systolic Function After Myocardial Infarction in RatsYoichi Sunagawa0Shogo Sono1Yasufumi Katanasaka2Masafumi Funamoto3Sae Hirano4Yusuke Miyazaki5Yuya Hojo6Hidetoshi Suzuki7Eriko Morimoto8Akira Marui9Ryuzo Sakata10Morio Ueno11Hideaki Kakeya12Hiromichi Wada13Koji Hasegawa14Tatsuya Morimoto15Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yata, Suruga-ku, Shizuoka 422-8526, Japan; Shizuoka General Hospital, 4-27-1, Kitaando, Aoi-ku, Shizuoka 420-8527, Japan; Division of Translational Research, Clinical Research Institute, Kyoto Medical Center, National Hospital Organization, 1-1, Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto 612-8555, JapanDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yata, Suruga-ku, Shizuoka 422-8526, JapanDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yata, Suruga-ku, Shizuoka 422-8526, Japan; Shizuoka General Hospital, 4-27-1, Kitaando, Aoi-ku, Shizuoka 420-8527, Japan; Division of Translational Research, Clinical Research Institute, Kyoto Medical Center, National Hospital Organization, 1-1, Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto 612-8555, JapanDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yata, Suruga-ku, Shizuoka 422-8526, JapanDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yata, Suruga-ku, Shizuoka 422-8526, Japan; Shizuoka Saiseikai General Hospital, 1-1-1, Oshika, Suruga-ku, Shizuoka 422-8527, JapanDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yata, Suruga-ku, Shizuoka 422-8526, JapanDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yata, Suruga-ku, Shizuoka 422-8526, JapanDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yata, Suruga-ku, Shizuoka 422-8526, JapanShizuoka General Hospital, 4-27-1, Kitaando, Aoi-ku, Shizuoka 420-8527, JapanDepartment of Cardiovascular Surgery, Graduate School of Medicine, Kyoto University, 54, Kawaramachi, Shogoin, Sakyo-ku, Kyoto 606-8507, JapanDepartment of Cardiovascular Surgery, Graduate School of Medicine, Kyoto University, 54, Kawaramachi, Shogoin, Sakyo-ku, Kyoto 606-8507, JapanDepartment of Ophthalmology, Kyoto Prefectural University of Medicine, 465, Kajii-cho, Teramachi-dori Hirokoji-dori agaru, Kamigyo-ku, Kyoto 602-8566, JapanDepartment of System Chemotherapy and Molecular Sciences, Division of Bioinformatics and Chemical Genomics, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida-Shimo-Adachi-cho, Sakyo-ku, Kyoto 606-8501, JapanDivision of Translational Research, Clinical Research Institute, Kyoto Medical Center, National Hospital Organization, 1-1, Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto 612-8555, JapanDivision of Translational Research, Clinical Research Institute, Kyoto Medical Center, National Hospital Organization, 1-1, Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto 612-8555, JapanDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yata, Suruga-ku, Shizuoka 422-8526, Japan; Shizuoka General Hospital, 4-27-1, Kitaando, Aoi-ku, Shizuoka 420-8527, Japan; Division of Translational Research, Clinical Research Institute, Kyoto Medical Center, National Hospital Organization, 1-1, Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto 612-8555, Japan; Corresponding author. morimoto@u-shizuoka-ken.ac.jpAbstract.: A natural p300-specific histone acetyltransferase inhibitor, curcumin, may have a therapeutic potential for heart failure. However, a study of curcumin to identify an appropriate dose for heart failure has yet to be performed. Rats were subjected to a left coronary artery ligation. One week later, rats with a moderate severity of myocardial infarction (MI) were randomly assigned to 4 groups receiving the following: a solvent as a control, a low dose of curcumin (0.5 mg∙kg−1∙day−1), a medium dose of curcumin (5 mg∙kg−1∙day−1), or a high dose of curcumin (50 mg∙kg−1∙day−1). Daily oral treatment was continued for 6 weeks. After treatment, left ventricular (LV) fractional shortening was dose-dependently improved in the high-dose (25.2% ± 1.6%, P < 0.001 vs. vehicle) and medium-dose (19.6% ± 2.4%) groups, but not in the low-dose group (15.5% ± 1.4%) compared with the vehicle group (15.1% ± 0.8%). The histological cardiomyocyte diameter and perivascular fibrosis as well as echocardiographic LV posterior wall thickness dose-dependently decreased in the groups receiving high and medium doses. The beneficial effects of oral curcumin on the post-MI LV systolic function are lower at 5 compared to 50 mg∙kg−1∙day−1 and disappear at 0.5 mg∙kg−1∙day−1. To clinically apply curcumin therapy for heart failure patients, a precise, optimal dose-setting study is required. Keywords:: curcumin, heart failure, hypertrophy, dose-dependency, p300http://www.sciencedirect.com/science/article/pii/S134786131930091X